Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Open access
Andreotti, Felicita, Rocca, Bianca, Husted, Steen, Ajjan, Ramzi A., ten Berg, Jurrien, Cattaneo, Marco, Collet, Jean-Philippe, De Caterina, Raffaele, Fox, Keith A.A., Halvorsen, Sigrun, Huber, Kurt, Hylek, Elaine M., Lip, Gregory Y.H., Montalescot, Gilles, Morais, Joao, Patrono, Carlo, Verheugt, Freek W.A., Wallentin, Lars, Weiss, Thomas W., Storey, Robert F. · 2015 · European Heart Journal

Abstract

Contemporary medicine is shifting towards person rather than disease-oriented care.1 With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2–6 There is general agreement that people ≥75 years can be defined ‘elderly’; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7–10 Moreover, ageing is a continuous process and life-span expansion is deflating (http://www.nber.org/papers/w18407). For these reasons, a threshold to define ‘elderly’ has been intentionally avoided in this document. Of note, over one third of patients admitted with acute myocardial infarction (MI) and two thirds dying from MI are over 75 years, but <7% of patients in ACS trials are reported ≥75 years.11 Older patients have multi-organ changes, increased risk of both bleeding and ischaemic events,3,5,12 frequent comorbidities/comedication, and reduced adherence to prescriptions. Given the challenges of antithrombotic treatment in the elderly, the European Society of Cardiology (ESC) Working Group on Thrombosis gathered a task group to address the topic. Antiplatelet, anticoagulant, and fibrinolytic drugs can prevent, postpone, or attenuate the severity of thrombotic events—namely stroke, transient ischaemic attack (TIA), MI, systemic embolism (SE), deep vein thrombosis (DVT), or pulmonary embolism (PE)—and retard cardiovascular and all-cause death, but at the cost of increased bleeding. The critical conundrum is whether, in the older patient, the benefits outweigh the …

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv304

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 241

Metadata

Authors
Andreotti, F., Rocca, B., Husted, S., Ajjan, R. A., ten Berg, J., Cattaneo, M., Collet, J.-P., De Caterina, R., Fox, K. A. A., Halvorsen, S., Huber, K., Hylek, E. M., Lip, G. Y. H., Montalescot, G., Morais, J., Patrono, C., Verheugt, F. W. A., Wallentin, L., Weiss, T. W., & Storey, R. F.
Venue
European Heart Journal
Published
2015-07-09
Volume
36
Issue
46
Pages
ehv304
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W1938064655
Cited by
241
References
20
FWCI
19.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. https://app.cochat.ai/papers/10.1093/eurheartj/ehv304
The paper
Andreotti, F., Rocca, B., Husted, S., Ajjan, R. A., ten Berg, J., Cattaneo, M., Collet, J.-P., De Caterina, R., Fox, K. A. A., Halvorsen, S., Huber, K., Hylek, E. M., Lip, G. Y. H., Montalescot, G., Morais, J., Patrono, C., Verheugt, F. W. A., Wallentin, L., Weiss, T. W., & Storey, R. F. (2015). Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv304

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.